<DOC>
	<DOCNO>NCT01406639</DOCNO>
	<brief_summary>This study patient recurrent epistaxis ( nosebleed ) result Hereditary Hemorrhagic Telangiectasia ( HHT ) . The aim determine ranibizumab , topically applied diminish epistaxis patient HHT measure HHT Epistaxis Severity Score ( ESS ) , hematocrit , hemoglobin serum ferritin level .</brief_summary>
	<brief_title>Ranibizumab Management Recurrent Nosebleeds Patients With Hereditary Hemorrhagic Telangiectasia ( HHT )</brief_title>
	<detailed_description>This open-label , Phase I study intranasal administer ranibizumab subject HHT . Plans recruit patient HHT UCSD Nasal Dysfunction Clinic . Those come evaluation deem appropriate topical ranibizumab without laser recruit study . Ten ( 10 ) consent , enrolled subject receive pulsatile nasal irrigator clean nose twice daily . They complete initial ESS blood test Hct , Hgb , serum ferritin , liver function test , renal function test child-bearing age , urine pregnancy test . They return 1 week later receive intranasal spray ranibizumab administer per week clinic . Patients treat total 4 application ranibizumab fine mist spray . This do 2 mgs 0.2cc ; 0.1cc spray nostril day ; therefore 8 mg require 4 day application . If , follow first treatment , experience recurrent bleeding ( equal less 75 % reduction ESS number compare pre treatment ) , offer opportunity prescribe second administration , complete way ( 4 application 4 mg 0.4 cc 0.2cc per nostril ) . At completion treatment , subject observe monthly examination ESS 6 month first treatment . At 3 6 month laboratory test perform .</detailed_description>
	<mesh_term>Telangiectasis</mesh_term>
	<mesh_term>Telangiectasia , Hereditary Hemorrhagic</mesh_term>
	<mesh_term>Epistaxis</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Inclusion Criteria Subjects eligible follow criterion meet : Ability provide write informed consent comply study assessment full duration study Age &gt; 18 year Diagnosed HHT Deemed appropriate topical Ranibizumab without laser , determine severity . For Ranibizumab effective , spray need reach nasal mucosa . Patients instruct nasal irrigation treat keep nose clean . Severe patient presumably achieve goal , subject patient moderate disease define epistaxis severity score sheet ( Appendix B ) Exclusion Criteria Subjects meet follow criterion exclude study : Coagulopathy Pregnancy ( positive pregnancy test ) lactation Premenopausal woman use adequate contraception . The following consider effective mean contraception : surgical sterilization use oral contraceptive , barrier contraception either condom diaphragm conjunction spermicidal gel , IUD , contraceptive hormone implant patch Any condition investigator believe would pose significant hazard subject investigational therapy initiate Participation another simultaneous medical investigation trial Patients bevacizumab therapy , injection , spray Patients know reaction base macular degeneration treatment Patients receive VEGF inhibitor last 2 year treatment ophthalmologic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Hereditary Hemorrhagic Telangiectasia ( HHT )</keyword>
	<keyword>Nosebleeds</keyword>
	<keyword>Ranibizumab</keyword>
	<keyword>Lucentis</keyword>
</DOC>